Inclusion Criteria:

- Subjects who meet the criteria guideline in the "Seasonal Influenza Prevention and
Control Manual" recommended by the Taiwan Centers for Disease Control, or are
determined by the investigator to have mild symptoms of COVID-19, including fever,
sore throat, cough, and fatigue.

- Subjects who have had a fever (body temperature ≥37.5°C and ≤39°C) before their
initial dose.

- Throat pain intensity score >30 points during the screening period.

- Cough severity score >3 points during the screening period.

- Fatigue level score >30 points during the screening period.

- Able to perform activities of daily living and aged 20 weeks or older.

- Duration of illness ≤24 hours.

- Obtained informed consent from the subject and signed the informed consent form.

Exclusion Criteria:

- Subject has used other medications for this condition (including cold medicine,
antibiotics, antiviral drugs, and similar traditional Chinese medicines) within the
24 hours prior to screening, or is determined by the investigator to require the use
of antibiotics or COVID-19 anti-virus drugs.

- Subject has used corticosteroids or NSAIDs for an extended period within the four
weeks prior to screening.

- Subject has had poorly controlled chronic diseases in the past five years, including
cardiovascular, respiratory, gastrointestinal, immune-related conditions, or mental
health disorders (as determined by the investigator).

- Subject has had chronic bronchitis, streptococcal pharyngitis, herpetic pharyngitis,
or pneumonia within the past two years or at the time of screening (as determined by
the investigator).

- Subject is allergic to the investigational drug or its components.

- Women who are pregnant, breastfeeding, or planning to become pregnant.

- Subject has participated in other drug clinical trials within the 90 days prior to
screening.

- The investigator evaluates the subject unsuitable for inclusion in the study.